Trial Profile
The effect of a beta-3 adrenergic receptor agonist on metabolic disease in humans.
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 16 Jul 2019
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary)
- Indications Metabolic disorders
- Focus Therapeutic Use
- 04 Sep 2018 New trial record